Join us for an exclusive private conference and cocktail reception: Discover VB Tech’s groundbreaking Digital Brain Twin

Editorial image

On November 4, 2025, VB Tech will offer guests an exclusive preview of their world’s first digital twin of the human brain — a breakthrough poised to transform neurological care and bring new hope to patients with drug-resistant epilepsy.

Organized in collaboration with Aix-Marseille University, the CIC, SYREC, the endowment fund "Les enfants de Catherine" and Rise Partners, the evening will feature presentations by Pierre Grand-Dufay and Viktor Jirsa, followed by a cocktail.

This exclusive event invites participants to connect with leading innovators and explore the future of brain medicine.

  • Contact and registration: l.otten@vb-tech.fr
  • Date: Tuesday, November 4, 2025
  • Time: 6:30 PM – 10:00 PM
  • Venue: CIC – 448 avenue du Prado, 13008 Marseille

VB Tech enters partnerships with UPMC Pittsburgh and UC Davis: 2 clinical centers of excellence for epilepsy in the USA

Our team flew to the USA to install the Hygie platform in these two centres and trained the clinicians and researchers to use Hygie in their daily work routine.

These new “Hubs” are from now on official Hygie ambassadors.

Logo UPMC
Logo UC Davis
Screenshot of Hygie software
Screenshot of Hygie software
Screenshot of Hygie software
Screenshot of Hygie software
Screenshot of Hygie software
Screenshot of Hygie software

VB Tech awarded the FrenchTech “Change the World” Prize

Screenshot of Hygie software

This award recognizes the potential to revolutionize the diagnosis and treatment of brain diseases thanks to its The Virtual Brain technology.

Related press releases:

VB Tech participates in new French Inserm program “Impact Santé”

VB Tech contributes a project called NAUTILUS (Neural Analysis Using Temporal Interference and Lifelike User Simulation).

It delivers highly personalized digital models of the brain that predict how each patient will respond to electrostimulation therapies—transforming care for conditions like epilepsy, depression, and Parkinson’s disease.

This groundbreaking approach brings us closer to truly personalized, effective, and precise neurological treatment.

Related press releases:

Interview with Viktor Jirsa